Danaher Corporation DHR shares are trading lower in the premarket session on Wednesday.

The company reported fourth-quarter adjusted earnings per share of $2.14 missing the street view of $2.16. Quarterly sales of $6.54 billion (+2%) beat the analyst consensus estimate of $6.42 billion.

The Biotechnology segment gained 6.5% year over year in the quarter under review, while the Life Sciences segment rose 5.5%. The Diagnostics segment sales decreased by 3% year over year.

The company exited the quarter with cash and equivalents worth $2.078 billion, and inventories worth $2.330 billion.

Also Read: Nasdaq Jumps 2% After Nvidia, Other Tech Stocks Bounce Back From DeepSeek Hit: Greed Index Remains In ‘Fear’ Zone

Danaher’s long-term debt as of quarter end totaled $15.50 billion. Operating cash flow was $2.0 billion in the fourth quarter and non-GAAP free cash flow was $1.5 billion.

Rainer M. Blair, President and Chief Executive Officer, stated, “Good execution by our team also drove solid cash flow and operating margin expansion.”

Outlook: Danaher expects its non-GAAP core revenue to decline by a low-single digit percentage year-over-year in the first quarter.

However, it anticipates a 3% year-over-year increase in core revenue for the full year of 2025.

Blair continued, “Looking ahead, we believe Danaher is better positioned than at any point in our 40-year history”. 

“The transformation in our portfolio over the last several years has created a focused life sciences and diagnostics innovator, poised for higher long-term growth, expanded margins and stronger cash flow.”

Price Action: DHR shares are trading lower by 5.48% to $234.26 premarket at last check Wednesday.

Read Next:

• Jim Cramer Recommends Buying ‘Fabulous' BlackRock, Calls Coterra Energy The ‘Cheapest' Natural Gas Company

Photo via Shutterstock.